首页 > 最新文献

Recent patents on biotechnology最新文献

英文 中文
Patents Selections 专利的选择
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-06-01 DOI: 10.2174/187220831703230306115220
{"title":"Patents Selections","authors":"","doi":"10.2174/187220831703230306115220","DOIUrl":"https://doi.org/10.2174/187220831703230306115220","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48621018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patents Selections 专利的选择
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-06-01 DOI: 10.2174/187220831702230302164332
{"title":"Patents Selections","authors":"","doi":"10.2174/187220831702230302164332","DOIUrl":"https://doi.org/10.2174/187220831702230302164332","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135381313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meet the Editorial Board Member 与编辑委员会成员见面
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-06-01 DOI: 10.2174/187220831702230302154730
Norman G. Lewis
{"title":"Meet the Editorial Board Member","authors":"Norman G. Lewis","doi":"10.2174/187220831702230302154730","DOIUrl":"https://doi.org/10.2174/187220831702230302154730","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135381312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meet the Editorial Board Member 与编辑委员会成员见面
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-03-01 DOI: 10.2174/187220831701221212163054
A. Galdino
{"title":"Meet the Editorial Board Member","authors":"A. Galdino","doi":"10.2174/187220831701221212163054","DOIUrl":"https://doi.org/10.2174/187220831701221212163054","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44348800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patents Selections 专利的选择
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-03-01 DOI: 10.2174/187220831701221212170557
{"title":"Patents Selections","authors":"","doi":"10.2174/187220831701221212170557","DOIUrl":"https://doi.org/10.2174/187220831701221212170557","url":null,"abstract":"","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136156700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proteome Exploration of Human Coronaviruses for Identifying Novel Vaccine Candidate: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach. 人类冠状病毒蛋白质组学研究用于鉴定新型候选疫苗:层次减法基因组学和反向疫苗学方法。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.2174/1872208316666220504234800
Hesam Dorosti, Mahboubeh Zarei, Navid Nezafat

Background: The SARS-CoV-2 has been responsible for infecting more than 613,615,658 people in 222 countries by September 11, 2022, of which 6,516,076 have died. COVID-19 was introduced by World Health Organization as a global concern and a pandemic disease due to its prevalence.

Objective: Developing preventive or therapeutic medications against 2019-nCoV is an urgent need, and has been deemed as a high priority among scientific societies; in this regard, the production of effective vaccines is one of the most significant and high-priority requirements. Because of costly and time-consuming process of vaccine design, different immunoinformatics methods have been developed.

Methods: At the beginning of vaccine design, the proteome study is essential. In this investigation, the whole human coronavirus proteome was evaluated using the proteome subtraction strategy. Out of 5945 human coronavirus proteins, five new antigenic proteins were selected by analyzing the hierarchical proteome subtraction, and then their various physicochemical and immunological properties were investigated bioinformatically.

Results: All five protein sequences are antigenic and non-allergenic proteins; moreover, the spike protein group, including spike glycoprotein (E2) (Peplomer protein), spike fragment and spike glycoprotein fragment, showed acceptable stability, which can be used to design new vaccines against human coronaviruses.

Conclusion: The selected peptides and the other proteins introduced in this study (HE, orf7a, SARS_X4 domain-containing protein and protein 8) can be employed as a suitable candidate for developing a novel prophylactic or therapeutic vaccine against human coronaviruses.

背景:截至2022年9月11日,SARS-CoV-2已在222个国家感染超过613,615,658人,其中6,516,076人死亡。COVID-19因其普遍性被世界卫生组织列为全球关注的疾病和大流行疾病。目的:开发针对新型冠状病毒的预防或治疗药物是迫切需要,已被科学界视为高度优先事项;在这方面,生产有效疫苗是最重要和最优先的要求之一。由于疫苗设计成本高、耗时长,人们开发了不同的免疫信息学方法。方法:在疫苗设计之初,蛋白质组学研究是必不可少的。本研究采用蛋白质组减法对整个人冠状病毒蛋白质组进行评估。从5945种人冠状病毒蛋白中,通过分层蛋白质组减法分析筛选出5种新的抗原蛋白,并对其理化和免疫学特性进行生物信息学研究。结果:5个蛋白序列均为抗原性、非致敏性蛋白;此外,包括刺突糖蛋白(E2) (Peplomer蛋白)、刺突片段和刺突糖蛋白片段在内的刺突蛋白组表现出可接受的稳定性,可用于设计新的抗人冠状病毒疫苗。结论:所筛选的多肽和本研究引入的其他蛋白(HE、orf7a、SARS_X4结构域蛋白和蛋白8)可作为开发新型冠状病毒预防或治疗性疫苗的合适候选蛋白。
{"title":"Proteome Exploration of Human Coronaviruses for Identifying Novel Vaccine Candidate: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.","authors":"Hesam Dorosti,&nbsp;Mahboubeh Zarei,&nbsp;Navid Nezafat","doi":"10.2174/1872208316666220504234800","DOIUrl":"https://doi.org/10.2174/1872208316666220504234800","url":null,"abstract":"<p><strong>Background: </strong>The SARS-CoV-2 has been responsible for infecting more than 613,615,658 people in 222 countries by September 11, 2022, of which 6,516,076 have died. COVID-19 was introduced by World Health Organization as a global concern and a pandemic disease due to its prevalence.</p><p><strong>Objective: </strong>Developing preventive or therapeutic medications against 2019-nCoV is an urgent need, and has been deemed as a high priority among scientific societies; in this regard, the production of effective vaccines is one of the most significant and high-priority requirements. Because of costly and time-consuming process of vaccine design, different immunoinformatics methods have been developed.</p><p><strong>Methods: </strong>At the beginning of vaccine design, the proteome study is essential. In this investigation, the whole human coronavirus proteome was evaluated using the proteome subtraction strategy. Out of 5945 human coronavirus proteins, five new antigenic proteins were selected by analyzing the hierarchical proteome subtraction, and then their various physicochemical and immunological properties were investigated bioinformatically.</p><p><strong>Results: </strong>All five protein sequences are antigenic and non-allergenic proteins; moreover, the spike protein group, including spike glycoprotein (E2) (Peplomer protein), spike fragment and spike glycoprotein fragment, showed acceptable stability, which can be used to design new vaccines against human coronaviruses.</p><p><strong>Conclusion: </strong>The selected peptides and the other proteins introduced in this study (HE, orf7a, SARS_X4 domain-containing protein and protein 8) can be employed as a suitable candidate for developing a novel prophylactic or therapeutic vaccine against human coronaviruses.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"17 2","pages":"163-175"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9463028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Basic Guidelines for Bacteriophage Isolation and Characterization. 噬菌体分离和鉴定的基本指南。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.2174/1872208317666221017094715
Safia Samir

The world is on the cusp of a post-antibiotic period. A century ago, before the advent of antibiotics, bacteriophage therapy was the treatment of choice for bacterial infections. Although bacteriophages have yet to be approved as a treatment in Western medicine, researchers and clinicians have begun to anticipate phage therapy. Bacteriophages are viruses that depend on bacterial cell metabolism to multiply. They offer a promising alternative to the use of antibiotics and an excellent antibacterial option for combating multidrug resistance in bacteria. However, not every phage is suitable for phage therapy. In particular, prophages should not be used because they can lysogenize host cells instead of lysing them. To offer adequate therapeutic options for patients suffering from various infectious diseases, a wide selection of different phages is needed. While there is no evidence of direct toxicity induced by phage particles, it is crucial to study mammalian cell-phage interactions. This requires phage preparations to be free of bacterial cells, toxins and other compounds to avoid skewing host responses. Negative staining of purified viruses and electron microscopy remain the gold standard in the identification of bacteriophages. Interestingly, genomics has greatly changed our understanding of phage biology. Bacteriophage genome sequencing is essential to obtain a complete understanding of the bacteriophages' biology and to obtain confirmation of their lifestyle. Full genetic sequencing of bacteriophage will enable a better understanding of the phage-encoded proteins and biomolecules (especially phage lytic enzymes) involved in the process of bacterial cell lysis and death. Mass spectrometry can be used for the identification of phage structural proteins. The use of lytic phages as biocontrol agents requires the most appropriate and standard methods to ensure application safety. This review pursues recent research and methods in molecular biology for the isolation and characterization of phages to facilitate follow-up and implementation of work for other researchers. Patents related to this topic have been mentioned in the text.

世界正处于后抗生素时代的风口浪尖。一个世纪前,在抗生素出现之前,噬菌体疗法是治疗细菌感染的首选疗法。尽管噬菌体尚未被批准作为一种西医治疗方法,但研究人员和临床医生已经开始期待噬菌体治疗。噬菌体是依靠细菌细胞代谢繁殖的病毒。它们为抗生素的使用提供了一个有希望的替代方案,也是对抗细菌多药耐药性的一个极好的抗菌选择。然而,并不是每个噬菌体都适合噬菌体治疗。特别是,不应该使用噬菌体,因为它们可以溶解宿主细胞而不是溶解它们。为了给患有各种传染病的患者提供适当的治疗选择,需要广泛选择不同的噬菌体。虽然没有证据表明噬菌体颗粒直接诱导毒性,但研究哺乳动物细胞-噬菌体相互作用至关重要。这就要求噬菌体制剂不含细菌细胞、毒素和其他化合物,以避免扭曲宿主的反应。纯化病毒的阴性染色和电子显微镜仍然是鉴定噬菌体的金标准。有趣的是,基因组学极大地改变了我们对噬菌体生物学的理解。噬菌体基因组测序对于全面了解噬菌体的生物学和确定它们的生活方式至关重要。噬菌体的全基因测序将使我们更好地了解噬菌体编码的蛋白质和生物分子(特别是噬菌体裂解酶)参与细菌细胞裂解和死亡的过程。质谱法可用于噬菌体结构蛋白的鉴定。使用噬菌体作为生物防治剂需要最合适和标准的方法来确保应用安全。本文综述了噬菌体分子生物学中分离和表征噬菌体的最新研究和方法,以促进其他研究人员的后续工作和实施。与此主题相关的专利已在文中提到。
{"title":"Basic Guidelines for Bacteriophage Isolation and Characterization.","authors":"Safia Samir","doi":"10.2174/1872208317666221017094715","DOIUrl":"https://doi.org/10.2174/1872208317666221017094715","url":null,"abstract":"<p><p>The world is on the cusp of a post-antibiotic period. A century ago, before the advent of antibiotics, bacteriophage therapy was the treatment of choice for bacterial infections. Although bacteriophages have yet to be approved as a treatment in Western medicine, researchers and clinicians have begun to anticipate phage therapy. Bacteriophages are viruses that depend on bacterial cell metabolism to multiply. They offer a promising alternative to the use of antibiotics and an excellent antibacterial option for combating multidrug resistance in bacteria. However, not every phage is suitable for phage therapy. In particular, prophages should not be used because they can lysogenize host cells instead of lysing them. To offer adequate therapeutic options for patients suffering from various infectious diseases, a wide selection of different phages is needed. While there is no evidence of direct toxicity induced by phage particles, it is crucial to study mammalian cell-phage interactions. This requires phage preparations to be free of bacterial cells, toxins and other compounds to avoid skewing host responses. Negative staining of purified viruses and electron microscopy remain the gold standard in the identification of bacteriophages. Interestingly, genomics has greatly changed our understanding of phage biology. Bacteriophage genome sequencing is essential to obtain a complete understanding of the bacteriophages' biology and to obtain confirmation of their lifestyle. Full genetic sequencing of bacteriophage will enable a better understanding of the phage-encoded proteins and biomolecules (especially phage lytic enzymes) involved in the process of bacterial cell lysis and death. Mass spectrometry can be used for the identification of phage structural proteins. The use of lytic phages as biocontrol agents requires the most appropriate and standard methods to ensure application safety. This review pursues recent research and methods in molecular biology for the isolation and characterization of phages to facilitate follow-up and implementation of work for other researchers. Patents related to this topic have been mentioned in the text.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"17 4","pages":"312-331"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9528606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Plant Extracts and Phytochemicals, a Promising Strategy Against Oral Lichen Planus: A Review on Clinical Trials. 植物提取物和植物化学物质:一种治疗口腔扁平苔藓的有前景的策略:临床试验综述。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.2174/1872208316666220718145421
Swati Gupta, Dr Lekshmi R Nath, Dr Sabitha M

Background: Oral lichen planus (OLP) is an autoimmune disease that distress keratinized cells of the oral epithelium. Topical corticosteroids and other potential therapies like immunosuppressives, hydroxychloroquine, azathioprine, mycophenolate, dapsone, retinoids, biologic agents are used for the management of OLP. However, their effectiveness, best dose, duration of treatment and safety remain mostly unidentified. Moreover, recurrence of disease and dose-related side effects are the other issues.

Objective: The primary objective of the review is to explore the existing clinical trials for the efficacy of phytochemicals in treating OLP in comparison to corticosteroids. A comprehensive information about their mode of action is also discussed.

Methods: We have discussed different clinical trials conducted on various phytochemicals and plant extracts/formulations like curcumin, lycopene, quercetin, glycyrrhizin, purslane, raspberry, aloe vera gel and aloe vera mouthwash for the treatment of OLP.

Results: The current therapy for the management of OLP has numerous adverse effects and requires a long-term treatment. Phytochemicals can be a very good alternative in overcoming these side effects and reducing the course of treatment.

Conclusion: Herbal extracts and their formulations can be an effective alternative to the current therapy due to their proven therapeutic effects, reduced side effects, long-term applicability, prevention of recurrence as well as progression into cancer.

背景:口腔扁平苔藓(OLP)是一种自身免疫性疾病,损害口腔上皮的角化细胞。局部皮质类固醇和其他潜在的治疗方法,如免疫抑制剂、羟氯喹、硫唑嘌呤、霉酚酸盐、氨苯砜、类维生素a、生物制剂等,被用于治疗OLP。然而,它们的有效性、最佳剂量、治疗持续时间和安全性大多尚未确定。此外,疾病复发和剂量相关的副作用是其他问题。目的:本综述的主要目的是探讨与皮质类固醇相比,植物化学物质治疗OLP疗效的现有临床试验。本文还讨论了它们的作用方式。方法:我们讨论了各种植物化学物质和植物提取物/配方,如姜黄素、番茄红素、槲皮素、甘草酸、马齿苋、覆盆子、芦荟凝胶和芦荟漱口水治疗OLP的不同临床试验。结果:目前治疗OLP的方法有许多不良反应,需要长期治疗。植物化学物质在克服这些副作用和缩短治疗过程方面是一个很好的选择。结论:中药提取物及其制剂具有疗效确切、副作用小、长期适用、预防复发和进展为癌症的特点,是目前治疗方法的有效替代。
{"title":"Plant Extracts and Phytochemicals, a Promising Strategy Against Oral Lichen Planus: A Review on Clinical Trials.","authors":"Swati Gupta,&nbsp;Dr Lekshmi R Nath,&nbsp;Dr Sabitha M","doi":"10.2174/1872208316666220718145421","DOIUrl":"https://doi.org/10.2174/1872208316666220718145421","url":null,"abstract":"<p><strong>Background: </strong>Oral lichen planus (OLP) is an autoimmune disease that distress keratinized cells of the oral epithelium. Topical corticosteroids and other potential therapies like immunosuppressives, hydroxychloroquine, azathioprine, mycophenolate, dapsone, retinoids, biologic agents are used for the management of OLP. However, their effectiveness, best dose, duration of treatment and safety remain mostly unidentified. Moreover, recurrence of disease and dose-related side effects are the other issues.</p><p><strong>Objective: </strong>The primary objective of the review is to explore the existing clinical trials for the efficacy of phytochemicals in treating OLP in comparison to corticosteroids. A comprehensive information about their mode of action is also discussed.</p><p><strong>Methods: </strong>We have discussed different clinical trials conducted on various phytochemicals and plant extracts/formulations like curcumin, lycopene, quercetin, glycyrrhizin, purslane, raspberry, aloe vera gel and aloe vera mouthwash for the treatment of OLP.</p><p><strong>Results: </strong>The current therapy for the management of OLP has numerous adverse effects and requires a long-term treatment. Phytochemicals can be a very good alternative in overcoming these side effects and reducing the course of treatment.</p><p><strong>Conclusion: </strong>Herbal extracts and their formulations can be an effective alternative to the current therapy due to their proven therapeutic effects, reduced side effects, long-term applicability, prevention of recurrence as well as progression into cancer.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"17 1","pages":"80-91"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10871339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effect of Captopril and BQ123 Endothelin-1 Antagonist on Experimentally Induced Hyperlipidemic Nephropathy in Rats. 卡托普利联合BQ123内皮素-1拮抗剂对实验性高脂血症大鼠肾病的影响。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.2174/1872208316666220629150347
Jaiswal A, Semwal Bc, Singh S

Background: Kidney disease is a universal public health problem, and epidemiological studies demonstrated that the incidences of chronic kidney disease are increasing day by day. However, the efficiency of currently available drugs on the progression of nephropathy is limited. Therefore, the current research was designed to evaluate the therapeutic efficacy of captopril and BQ123 against hyperlipidemia-induced nephropathy in rats.

Objective: The objective of this study was to examine the implication of Endothelin-1 in experimentally induced hyperlipidemic nephropathy in rats.

Methods: Animals were divided into various groups, and the administration of a high-fat diet for six weeks induced hyperlipidemia. After confirmation of hyperlipidemia, treatment was started for the next 14 days. At the end of the experimental period, the animals were sacrificed, and various biochemical parameters and histopathological studies were performed.

Results: Treatment of both the agents in combination effectively decreased BUN levels, serum creatinine, serum nitrite, and proinflammatory markers and ameliorated the pathological injuries to kidneys.

Conclusion: Furthermore, both treatments also inhibited oxidative stress and restored the hyperlipidemia-induced reduction in the level of antioxidant enzymes.

背景:肾脏疾病是一个普遍的公共卫生问题,流行病学研究表明慢性肾脏疾病的发病率日益增加。然而,目前可用的药物对肾病进展的有效性是有限的。因此,本研究旨在评价卡托普利和BQ123对大鼠高脂血症肾病的治疗效果。目的:探讨内皮素-1在实验性高脂血症大鼠中的作用。方法:将实验动物分为不同的组,给予高脂饮食6周诱导高脂血症。确诊为高脂血症后,开始治疗14天。实验结束时,处死动物,进行各项生化参数和组织病理学检查。结果:两种药物联合治疗可有效降低BUN水平、血清肌酐、血清亚硝酸盐及促炎指标,改善肾脏病理损伤。结论:两种处理均能抑制氧化应激,恢复高脂血症引起的抗氧化酶水平下降。
{"title":"Effect of Captopril and BQ123 Endothelin-1 Antagonist on Experimentally Induced Hyperlipidemic Nephropathy in Rats.","authors":"Jaiswal A,&nbsp;Semwal Bc,&nbsp;Singh S","doi":"10.2174/1872208316666220629150347","DOIUrl":"https://doi.org/10.2174/1872208316666220629150347","url":null,"abstract":"<p><strong>Background: </strong>Kidney disease is a universal public health problem, and epidemiological studies demonstrated that the incidences of chronic kidney disease are increasing day by day. However, the efficiency of currently available drugs on the progression of nephropathy is limited. Therefore, the current research was designed to evaluate the therapeutic efficacy of captopril and BQ123 against hyperlipidemia-induced nephropathy in rats.</p><p><strong>Objective: </strong>The objective of this study was to examine the implication of Endothelin-1 in experimentally induced hyperlipidemic nephropathy in rats.</p><p><strong>Methods: </strong>Animals were divided into various groups, and the administration of a high-fat diet for six weeks induced hyperlipidemia. After confirmation of hyperlipidemia, treatment was started for the next 14 days. At the end of the experimental period, the animals were sacrificed, and various biochemical parameters and histopathological studies were performed.</p><p><strong>Results: </strong>Treatment of both the agents in combination effectively decreased BUN levels, serum creatinine, serum nitrite, and proinflammatory markers and ameliorated the pathological injuries to kidneys.</p><p><strong>Conclusion: </strong>Furthermore, both treatments also inhibited oxidative stress and restored the hyperlipidemia-induced reduction in the level of antioxidant enzymes.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"17 2","pages":"151-162"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9833988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antidiabetic Agents from Fungi with Special Reference to α-Glucosidase Inhibitors. 真菌抗糖尿病药物,特别是α-葡萄糖苷酶抑制剂。
Q3 Biochemistry, Genetics and Molecular Biology Pub Date : 2023-01-01 DOI: 10.2174/1872208316666220512122439
Sunil Kumar Deshmukh, Manish Kumar Gupta, Shivankar Agrawal

The enzyme α-glucosidases (EC 3.2.1.20) catalyzes the hydrolysis of α-1,4- glucopyranoside bond in oligosaccharides and disaccharides, and thus plays an essential role in regulating glucose content and the level of postprandial hyperglycemia. The inhibition of α-glucosidases is considered a viable strategy to develop new and effective antidiabetic drugs. Many patents like ZA201905405B; US9073897B2 have been published on α- glucosidase inhibitors. In recent years, several classes of fungal metabolites possessing a varying degree of α-glucosidases inhibitory activity have been reported. The primary chemical classes include xanthone, phenanthrene, terpenoid, coumarin, isocoumarin, naphthalene, piperazine, and polyketides. Few of the identified inhibitors exhibited severalfold better activities than well-known α-glucosidases inhibitor acarbose and can be used as a lead to develop new antidiabetic drugs. The present review highlights the recent development in the identification of α-glucosidases inhibitors from various fungal sources. Their chemical class, structures, and inhibitory activity in terms of IC50 or MIC are discussed here.

α-葡萄糖苷酶(EC 3.2.1.20)催化水解低聚糖和双糖中的α-1,4-葡萄糖苷键,在调节葡萄糖含量和餐后高血糖水平中起重要作用。抑制α-葡萄糖苷酶被认为是开发新型有效降糖药的可行策略。ZA201905405B等多项专利;US9073897B2已发表的α-葡萄糖苷酶抑制剂。近年来,已经报道了几种具有不同程度α-葡萄糖苷酶抑制活性的真菌代谢物。主要的化学类包括山酮、菲、萜类、香豆素、异香豆素、萘、哌嗪和聚酮。所鉴定的几种抑制剂的活性比已知的α-葡萄糖苷酶抑制剂阿卡波糖好几倍,可以作为开发新型降糖药的先导。本文综述了从不同真菌源中鉴定α-葡萄糖苷酶抑制剂的最新进展。本文讨论了它们的化学类别、结构和IC50或MIC的抑制活性。
{"title":"Antidiabetic Agents from Fungi with Special Reference to α-Glucosidase Inhibitors.","authors":"Sunil Kumar Deshmukh,&nbsp;Manish Kumar Gupta,&nbsp;Shivankar Agrawal","doi":"10.2174/1872208316666220512122439","DOIUrl":"https://doi.org/10.2174/1872208316666220512122439","url":null,"abstract":"<p><p>The enzyme α-glucosidases (EC 3.2.1.20) catalyzes the hydrolysis of α-1,4- glucopyranoside bond in oligosaccharides and disaccharides, and thus plays an essential role in regulating glucose content and the level of postprandial hyperglycemia. The inhibition of α-glucosidases is considered a viable strategy to develop new and effective antidiabetic drugs. Many patents like ZA201905405B; US9073897B2 have been published on α- glucosidase inhibitors. In recent years, several classes of fungal metabolites possessing a varying degree of α-glucosidases inhibitory activity have been reported. The primary chemical classes include xanthone, phenanthrene, terpenoid, coumarin, isocoumarin, naphthalene, piperazine, and polyketides. Few of the identified inhibitors exhibited severalfold better activities than well-known α-glucosidases inhibitor acarbose and can be used as a lead to develop new antidiabetic drugs. The present review highlights the recent development in the identification of α-glucosidases inhibitors from various fungal sources. Their chemical class, structures, and inhibitory activity in terms of IC<sub>50</sub> or MIC are discussed here.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":"17 1","pages":"24-61"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10872040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Recent patents on biotechnology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1